Published in Hypertension on April 05, 2010
ROS-induced ROS release in vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol (2011) 1.11
Role of the transcription factor erythroblastosis virus E26 oncogen homolog-1 (ETS-1) as mediator of the renal proinflammatory and profibrotic effects of angiotensin II. Hypertension (2012) 0.85
Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. PLoS One (2012) 0.82
The transcription factor E26 transformation-specific sequence-1 mediates neointima formation in arteriovenous fistula. J Am Soc Nephrol (2013) 0.82
Stimulatory interactions between human coronary smooth muscle cells and dendritic cells. PLoS One (2014) 0.76
Transcription factor avian erythroblastosis virus E26 oncogen homolog-1 is a novel mediator of renal injury in salt-sensitive hypertension. Hypertension (2015) 0.76
Inflammation in atherosclerosis. Nature (2002) 28.92
Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature (1984) 4.99
The Ets family of transcription factors. Eur J Biochem (1993) 4.74
Molecular biology of the Ets family of transcription factors. Gene (2003) 4.41
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 4.36
ETS transcription factors and their emerging roles in human cancer. Eur J Cancer (2005) 3.55
Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci (1998) 2.75
Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem (2002) 2.15
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest (2005) 1.89
Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation (2000) 1.84
Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res (2007) 1.79
Definition of an Ets1 protein domain required for nuclear localization in cells and DNA-binding activity in vitro. Mol Cell Biol (1989) 1.67
Determination of temporal expression patterns for multiple genes in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol (2000) 1.51
Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev (2000) 1.48
Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res (2002) 1.45
Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene (1997) 1.41
Regulation of vascular inflammation and remodeling by ETS factors. Circ Res (2006) 1.33
ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol (1999) 1.28
Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation (2004) 1.26
Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation (1996) 1.25
Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ Res (1996) 1.19
Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation (2003) 1.16
Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol (2000) 1.15
TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis (2001) 1.14
Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol (1998) 1.07
Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum (2001) 1.06
Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. Circ Res (2004) 1.01
Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause (2007) 1.01
Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res (2002) 1.00
Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood (2005) 0.97
Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. Am J Physiol Renal Physiol (2008) 0.95
Expression of phenotype- and proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc Res (1997) 0.89
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 2.85
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) (2012) 2.67
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 2.60
Detection and avoidance of a natural product from the pathogenic bacterium Serratia marcescens by Caenorhabditis elegans. Proc Natl Acad Sci U S A (2007) 2.56
Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res (2013) 2.55
NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev (2011) 2.53
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst (2003) 2.49
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res (2011) 2.44
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Structural basis of the alpha1-beta subunit interaction of voltage-gated Ca2+ channels. Nature (2004) 2.38
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther (2014) 2.16
Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell (2005) 2.16
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Duct-to-mucosa versus invagination pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis. Chin Med J (Engl) (2013) 1.99
Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov (2002) 1.98
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells. Immunogenetics (2005) 1.95
Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest (2005) 1.94
Prevalence of prehypertension and hypertension in a Chinese rural area from 1991 to 2007. Hypertens Res (2010) 1.90
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol (2009) 1.90
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest (2013) 1.88
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 1.85
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med (2006) 1.82
Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol (2007) 1.80
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 1.79
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. J Clin Hypertens (Greenwich) (2014) 1.72
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
In vivo regulation of the heme oxygenase-1 gene in humanized transgenic mice. Kidney Int (2012) 1.67
Clustering of syringe sharing and unprotected sex risk behaviors in male injecting drug users in China. Sex Transm Dis (2007) 1.66
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol (2012) 1.64
Prevalence of bisexual behaviors among men who have sex with men (MSM) in China and associations between condom use in MSM and heterosexual behaviors. Sex Transm Dis (2008) 1.63
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61
Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer (2010) 1.59
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat Med (2012) 1.58
Meta-analysis of aldehyde dehydrogenase 2 gene polymorphism and Alzheimer's disease in East Asians. Can J Neurol Sci (2011) 1.56
TNF-alpha suppresses prolyl-4-hydroxylase alpha1 expression via the ASK1-JNK-NonO pathway. Arterioscler Thromb Vasc Biol (2007) 1.55
Genome of the Chinese tree shrew. Nat Commun (2013) 1.55
Effect of adiponectin overexpression on stability of preexisting plaques by inducing prolyl-4-hydroxylase expression. Circ J (2010) 1.54
Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens (2007) 1.54
Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms. J Urol (2012) 1.54
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53
BDNF Val66Met polymorphism is associated with unstable angina. Clin Chim Acta (2008) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol (2010) 1.51
The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res (2002) 1.51
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2002) 1.51
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (2005) 1.49
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis (2005) 1.48
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res (2009) 1.47
Usefulness of high-frequency vascular ultrasound imaging and serum inflammatory markers to predict plaque rupture in patients with stable and unstable angina pectoris. Am J Cardiol (2007) 1.46